Regorafenib is a multi-kinase inhibitor targeting angiogenic (VEGFR, TIE-2), stromal (PDGFR-β) and oncogenic (RAF, RET and c-KIT) receptor tyrosine kinases, with IC50s of 17, 40 and 69 nM for c-KIT, VEGFR2, B-Raf, respectively. Displays potential antiangiogenic and antineoplastic activities. MW: 482.81. Purity ≥98% by HPLC
Size
25 mg
Concentration
n/a
Applications
n/a
Other Names
4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY 73-4506